Loading company
Elicio Therapeutics, Inc.
ELTX · Nasdaq · ·
$1.850.0%Sep 29 close
- 1M
- -34.9%
- 6M
- -81.6%
- 1Y
- -83.1%
- 5Y
- -98.2%
ELTX · Nasdaq · ·
$1.850.0%Sep 29 close
The quarter ending March 31, 2023, against the same quarter a year earlier.
| Measure | 3 months toMar 31, 2023 | 3 months toMar 31, 2022 | Change |
|---|---|---|---|
| Total Revenue | $0.00 | $1.6M | -100.00% |
| Profit | -$8.2M | -$10.6M | +22.19% |
| Profit per share | -$0.43 | -$0.66 | +34.85% |
| Free Cash Flow | -$6.8M | -$9M | +24.05% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
Elicio Therapeutics, Inc. has no earnings call transcript available.
“The encouraging clinical observations reported to date, including multiple complete responses following ELI-002 7P treatment and subsequent checkpoint inhibition, further support the promise of our AMP platform approach and its potential to generate durable anti-tumor immune responses,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land after the close or before the open, so the move is the session that follows.
The quote and the company description come from Elicio Therapeutics, Inc.’s Item 2.02 8-K filed August 13, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.